Noxopharm (Noxopharm) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Noxopharm Short-Term Debt?

Noxopharm's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Noxopharm's quarterly Short-Term Debt declined from Dec. 2022 ($0.01 Mil) to Jun. 2023 ($0.00 Mil) but then stayed the same from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Noxopharm Short-Term Debt Historical Data

The historical data trend for Noxopharm's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Short-Term Debt Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

2.73

3.00

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial										0.20	-	0.01	-	-

Noxopharm Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Noxopharm Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Noxopharm's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (Noxopharm) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (OTCPK:NOXOF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

NOX:Australia

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.